Senti Bio Announces Reverse Stock SplitShares expected to begin trading on split-adjusted basis on July 18, 2024
Complete Solaria, Senti, and POET: 3 High Volume Penny StocksPenny stocks are risky, but follow the money to find winners. Stocks with significant volume spikes may have what it takes for higher share prices.
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 –
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 –
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024 –
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates– IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 –
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting- Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability of oncology cell therapies -
Senti Bio to Participate in Upcoming ConferencesSOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced its participation at the following investor and healthcare industry conferences:
Senti Bio to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences:
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates– GeneFab transaction provides access to clinical manufacturing and extends cash runway into Q4 2024 –
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners– Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies –
Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingFive presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages
Senti Bio Announces First Quarter 2023 Results and Pipeline Updates– New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission and clearance in 2H 2023 –
Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting- Four abstracts accepted show the potential of applying gene circuits in multiple cell and gene therapy modalities for neurology, ophthalmology, and oncology -
Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting– Preclinical data supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission in 2H 2023 –
Senti Bio to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences:
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Senti Bioscience, Inc. (SNTI) Investigation
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dynamics Special Purpose Corp., which merged with Senti Bioscience, Inc. ("Senti" or "the Company") (
NASDAQSNTI) on June 8, 2022. Such investors who continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/snti.
Senti Biosciences Announces New Employment Inducement GrantsSOUTH SAN FRANCISCO, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced that effective on February 1, 2023, the Compensation Committee of Senti Bio’s Board of Directors granted to 13 new employees stock options to purchase an aggregate of 309,000 shares of the Company’s common stock with a per share exercise price of $1.81. These awards were made under the Company’s 2022 Inducement Equity Plan (the Plan).
Senti Bio to Present at the SVB Securities Global Biopharma ConferenceSOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced that Tim Lu, MD, PhD, Senti’s Co-Founder and CEO, will present at the SVB Securities Global Biopharma Conference.
